Upadacitinib Earns FDA Approval for Ankylosing Spondylitis

Janus kinase inhibitor offers oral option for patients who have failed treatment.
FDA Approvals

source https://www.medscape.com/viewarticle/973230?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension